{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T17:30:45Z","timestamp":1771867845688,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T00:00:00Z","timestamp":1130803200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1124\/dmd.105.005579","type":"journal-article","created":{"date-parts":[[2005,7,28]],"date-time":"2005-07-28T00:33:41Z","timestamp":1122510821000},"page":"1637-1647","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":88,"title":["AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS"],"prefix":"10.1016","volume":"33","author":[{"given":"Anthony","family":"Atkinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jane R.","family":"Kenny","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Grime","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.105.005579_bib1","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1124\/dmd.30.12.1497","article-title":"The influence of nonspecific microsomal binding on apparent intrinsic clearance and its prediction from physicochemical properties.","volume":"30","author":"Austin","year":"2002","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib2","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1016\/0006-2952(94)00477-4","article-title":"Particular ability of cytochromes P450 3A to form inhibitory P450-iron-metabolite complexes upon metabolic oxidation of aminodrugs.","volume":"49","author":"Bensoussan","year":"1995","journal-title":"Biochem Pharmacol"},{"key":"10.1124\/dmd.105.005579_bib3","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1124\/dmd.31.3.289","article-title":"Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: comparison with fluoxetine and quinidine.","volume":"31","author":"Bertelsen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib4","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1124\/dmd.31.7.815","article-title":"The conduct of in vitro and in vivo drug-drug interaction studies: a Pharmaceutical Research and Manufacturers of America (PhRMA) perspective.","volume":"31","author":"Bjornsson","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib5","series-title":"Drug-Drug Interactions, vol 166: Drugs and the Pharmaceutical Sciences","first-page":"549","article-title":"Development of a metabolic drug interaction database at the University of Washington","author":"Carlson","year":"2002"},{"key":"10.1124\/dmd.105.005579_bib6","first-page":"8164","article-title":"A new selective and potent inhibitor of human cytochrome P450 1B1 and its application to antimutagenesis.","volume":"61","author":"Chun","year":"2001","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.105.005579_bib7","first-page":"389","article-title":"Mechanism-based inhibition of human cytochrome P450 1A1 by rhapontigenin.","volume":"29","author":"Chun","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib8","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1124\/dmd.31.8.1005","article-title":"In vitro drug interactions of cytochrome P450: an evaluation of fluorogenic to conventional substrates.","volume":"31","author":"Cohen","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib9","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/S1056-8719(00)00112-X","article-title":"Fluorometric screening for metabolism-based drug\u2013drug interactions.","volume":"44","author":"Crespi","year":"2000","journal-title":"J Pharmacol Toxicol Methods"},{"key":"10.1124\/dmd.105.005579_bib10","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1124\/dmd.31.1.28","article-title":"Mechanism-based inactivation of cytochrome P450 2B6 by a novel terminal acetylene inhibitor.","volume":"31","author":"Fan","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib11","first-page":"227","article-title":"Inhibition of mixed-function oxidations by substrates forming reduced cytochrome P-450 metabolic-intermediate complexes.","volume":"2","author":"Franklin","year":"1977","journal-title":"Pharmacol Ther"},{"key":"10.1124\/dmd.105.005579_bib12","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1007\/978-1-4615-0667-6_18","article-title":"Inhibition by ticlopidine and its derivatives of human liver cytochrome P450. Mechanism-based inactivation of CYP 2C19 by ticlopidine.","volume":"500","author":"Ha-Duong","year":"2001","journal-title":"Adv Exp Med Biol"},{"key":"10.1124\/dmd.105.005579_bib13","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1081\/DMR-120001387","article-title":"Characteristics and common properties of inhibitors, inducers and activators of CYP [cytochrome P 450] enzymes.","volume":"34","author":"Hollenberg","year":"2002","journal-title":"Drug Metab Rev"},{"key":"10.1124\/dmd.105.005579_bib14","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1046\/j.1365-2125.1999.00073.x","article-title":"CYP3A4 drug interactions: correlation of 10 in vitro probe substrates.","volume":"48","author":"Kenworthy","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.005579_bib15","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1042\/bj2250435","article-title":"Inhibition of class C beta-lactamases by (1\u2032R,6R)-6-(1\u2032-hydroxy)benzylpenicillanic acid SS-dioxide.","volume":"225","author":"Knight","year":"1985","journal-title":"Biochem J"},{"key":"10.1124\/dmd.105.005579_bib16","doi-asserted-by":"crossref","first-page":"10047","DOI":"10.1021\/bi980003c","article-title":"Mechanism-based inactivation of P450 2A6 by furanocoumarins.","volume":"37","author":"Koenigs","year":"1998","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.105.005579_bib17","doi-asserted-by":"crossref","first-page":"504","DOI":"10.5414\/CPP38504","article-title":"Drug-drug interactions in medical patients: effects of in-hospital treatment and relation to multiple drug use.","volume":"38","author":"Kohler","year":"2000","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.105.005579_bib18","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1021\/tx00035a009","article-title":"Isoform-selective mechanism-based inhibition of human cytochrome P450 1A2 by furafylline.","volume":"6","author":"Kunze","year":"1993","journal-title":"Chem Res Toxicol"},{"key":"10.1124\/dmd.105.005579_bib19","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1001\/jama.279.15.1200","article-title":"Incidence of adverse drug reactions in hospitalized patients: a meta-analysis of prospective studies.","volume":"279","author":"Lazarou","year":"1998","journal-title":"J Am Med Assoc"},{"key":"10.1124\/dmd.105.005579_bib20","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2165\/00003088-199835050-00003","article-title":"Inhibition and induction of cytochrome P450 and the clinical implications.","volume":"35","author":"Lin","year":"1998","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.105.005579_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1021\/bi00167a022","article-title":"Thiophene derivatives as new mechanism-based inhibitors of cytochromes P450: inactivation of yeast expressed human liver cytochrome P450 2C9 by tienilic acid.","volume":"33","author":"Lopez-Garcia","year":"1994","journal-title":"Biochemistry"},{"key":"10.1124\/dmd.105.005579_bib22","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1124\/dmd.31.11.1352","article-title":"Mechanism-based inhibition of human liver microsomal cytochrome P450 1A2 by zileuton, a 5-lipoxygenase inhibitor.","volume":"31","author":"Lu","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib23","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1124\/dmd.32.10.1083","article-title":"Differences in the inhibition of cytochromes P450 3A4 and 3A5 by metabolite-inhibitor complex-forming drugs.","volume":"32","author":"McConn","year":"2004","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib24","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1080\/004982599238812","article-title":"Fully automated analysis of activities catalyzed by the major human liver cytochrome P450 (CYP) enzymes: assessment of human CYP inhibition potential.","volume":"29","author":"Moody","year":"1999","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.005579_bib25","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2133\/dmpk.19.55","article-title":"Utility of microtiter plate assays for human cytochrome P450 inhibition studies in drug discovery: application of simple method for detecting quasi-irreversible and irreversible inhibitors.","volume":"19","author":"Naritomi","year":"2004","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.105.005579_bib26","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/S0090-9556(25)06500-6","article-title":"Cytochrome P450 inhibitors: evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes.","volume":"23","author":"Newton","year":"1995","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib27","first-page":"99","article-title":"Suicide inhibitors for drug metabolising enzymes: mechanisms and biological consequences.","volume":"111","author":"Ortiz de Montellano","year":"1988","journal-title":"Prog Drug Metab"},{"key":"10.1124\/dmd.105.005579_bib28","first-page":"863","article-title":"Mechanism-based inactivation of CYP2D6 by 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine.","volume":"29","author":"Palamanda","year":"2001","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib29","doi-asserted-by":"crossref","first-page":"996","DOI":"10.1124\/jpet.104.071803","article-title":"Mechanism-based inactivation of human cytochrome P4502C8 by drugs in vitro.","volume":"311","author":"Polasek","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1124\/dmd.105.005579_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1006\/abbi.2001.2401","article-title":"Covalent alteration of the CYP3A4 active site: evidence for multiple substrate binding domains.","volume":"391","author":"Schrag","year":"2001","journal-title":"Arch Biochem Biophys"},{"key":"10.1124\/dmd.105.005579_bib31","series-title":"Enzyme Kinetics: Behavior and Analysis of Rapid Equilibrium and Steady-State Enzyme Systems.","author":"Segel","year":"1975"},{"key":"10.1124\/dmd.105.005579_bib32","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1080\/004982598238859","article-title":"Human cytochrome P450s: selectivity and measurement in vivo.","volume":"28","author":"Smith","year":"1998","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.005579_bib33","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1046\/j.1365-2125.2003.01721.x","article-title":"A comparison of relative abundance, activity factor and inhibitory monoclonal antibody approaches in the characterization of human CYP enzymology.","volume":"55","author":"Soars","year":"2003","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.105.005579_bib34","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1067\/mcp.2001.116891","article-title":"Optimizing drug development: strategies to assess drug metabolism\/transporter interaction potential\u2014toward a consensus.","volume":"70","author":"Tucker","year":"2001","journal-title":"Clin Pharm Ther"},{"key":"10.1124\/dmd.105.005579_bib35","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1042\/bj2270843","article-title":"Kinetics of suicide substrates. Practical procedures for determining parameters.","volume":"227","author":"Waley","year":"1985","journal-title":"Biochem J"},{"key":"10.1124\/dmd.105.005579_bib36","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1124\/dmd.31.7.955","article-title":"Cytochrome P450 inhibition using recombinant proteins and mass spectrometry\/multiple reaction monitoring technology in a cassette incubation.","volume":"31","author":"Weaver","year":"2003","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.105.005579_bib37","doi-asserted-by":"crossref","first-page":"437","DOI":"10.2133\/dmpk.17.437","article-title":"Application of microtiter plate assay to evaluate inhibitory effects of various compounds on nine cytochrome P450 isoforms and to estimate their inhibition patterns.","volume":"17","author":"Yamamoto","year":"2002","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.105.005579_bib38","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1080\/004982500237749","article-title":"Automated high throughput human CYP isoform activity assay using SPE-LC\/MS method: application in CYP inhibition evaluation.","volume":"30","author":"Yin","year":"2000","journal-title":"Xenobiotica"},{"key":"10.1124\/dmd.105.005579_bib39","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2174\/1389200043335450","article-title":"Therapeutic drugs that behave as mechanism-based inhibitors of cytochrome P450 3A4.","volume":"5","author":"Zhou","year":"2004","journal-title":"Curr Drug Metab"},{"key":"10.1124\/dmd.105.005579_bib40","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-200544030-00005","article-title":"Mechanism-based inhibition of cytochrome P450 3A4 by therapeutic drugs.","volume":"44","author":"Zhou","year":"2005","journal-title":"Clin Pharmacokinet"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624033129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624033129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.105.005579","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T17:55:48Z","timestamp":1739901348000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624033129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11]]},"references-count":40,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["S0090955624033129"],"URL":"https:\/\/doi.org\/10.1124\/dmd.105.005579","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2005,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AUTOMATED ASSESSMENT OF TIME-DEPENDENT INHIBITION OF HUMAN CYTOCHROME P450 ENZYMES USING LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY ANALYSIS","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.105.005579","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2005 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}